Biomarker Levels Prognostic for Septic Patients
|
By LabMedica International staff writers Posted on 17 Sep 2012 |
|
An elevation in soluble urokinase-type plasminogen activator receptor (suPAR) levels may predict case fatality and is associated with severe sepsis.
The suPAR protein levels in the blood and other biomarkers, such as procalcitonin, have been evaluated as early prognostic markers of sepsis in patients with suspected infection
At the Satakunta Central Hospital (Pori, Finland) scientists conducted a prospective cohort study on 539 patients in the emergency department with suspected infection. The patients were divided into the following groups: in group1 comprised of 59 patients without systemic inflammatory response syndrome (SIRS) and without bacterial infection; group 2 were 68 patients with bacterial infection and without SIRS; group 3 were 54 patients with SIRS and without bacterial infection; group 4 were 309 patients with sepsis (SIRS and bacterial infection) and without organ failure and Group 5 were 49 patients with severe sepsis (SIRS, bacterial infection and organ failure.
Plasma suPAR levels were determined using a commercial double monoclonal antibody sandwich enzyme immunoassay (suPARnostic Standard Kit, ViroGates; Birkerød, Denmark). Procalcitonin (PCT) and interleukin-6 (IL-6) in plasma were measured with immunochemiluminometric assays in a Modular E170 automatic analyzer (Roche Diagnostics GmbH, Mannheim, Germany). C-reactive protein (CRP) in plasma was measured with an immunoturbidimetric assay using a Roche Diagnostics Modular P800 automatic analyzer.
The median suPAR concentrations were 4.7, 5.0, 4.4, 4.8, and 7.9 ng/mL in groups 1 through 5, respectively and levels were found to be significantly higher at 8.3 ng/mL in nonsurvivors compared with in survivors at 4.9 ng/mL. The suPAR level was found to have 76% sensitivity and 69% specificity for fatal disease, using a cut-off level of 6.4 ng/mL and 67% and 72% sensitivity and specificity, respectively, for severe sepsis at a cut-off level of 6.6 ng/mL. The scientists also evaluated PCT, interleukin 6, and C-reactive protein in this patient population and found that although suPAR was the best biomarker for case fatality, in further statistical analysis, PCT was a superior marker for severe sepsis.
The authors concluded, "It is tempting to think that measurement of suPAR may be used for triage to determine which patients with sepsis may require more comprehensive monitoring, as high suPAR levels in the emergency department may predict the need for more intensive therapeutic intervention." The study was published in the September 2012 issue of the Journal of Internal Medicine.
Related Links:
Satakunta Central Hospital
ViroGates
Roche Diagnostics
The suPAR protein levels in the blood and other biomarkers, such as procalcitonin, have been evaluated as early prognostic markers of sepsis in patients with suspected infection
At the Satakunta Central Hospital (Pori, Finland) scientists conducted a prospective cohort study on 539 patients in the emergency department with suspected infection. The patients were divided into the following groups: in group1 comprised of 59 patients without systemic inflammatory response syndrome (SIRS) and without bacterial infection; group 2 were 68 patients with bacterial infection and without SIRS; group 3 were 54 patients with SIRS and without bacterial infection; group 4 were 309 patients with sepsis (SIRS and bacterial infection) and without organ failure and Group 5 were 49 patients with severe sepsis (SIRS, bacterial infection and organ failure.
Plasma suPAR levels were determined using a commercial double monoclonal antibody sandwich enzyme immunoassay (suPARnostic Standard Kit, ViroGates; Birkerød, Denmark). Procalcitonin (PCT) and interleukin-6 (IL-6) in plasma were measured with immunochemiluminometric assays in a Modular E170 automatic analyzer (Roche Diagnostics GmbH, Mannheim, Germany). C-reactive protein (CRP) in plasma was measured with an immunoturbidimetric assay using a Roche Diagnostics Modular P800 automatic analyzer.
The median suPAR concentrations were 4.7, 5.0, 4.4, 4.8, and 7.9 ng/mL in groups 1 through 5, respectively and levels were found to be significantly higher at 8.3 ng/mL in nonsurvivors compared with in survivors at 4.9 ng/mL. The suPAR level was found to have 76% sensitivity and 69% specificity for fatal disease, using a cut-off level of 6.4 ng/mL and 67% and 72% sensitivity and specificity, respectively, for severe sepsis at a cut-off level of 6.6 ng/mL. The scientists also evaluated PCT, interleukin 6, and C-reactive protein in this patient population and found that although suPAR was the best biomarker for case fatality, in further statistical analysis, PCT was a superior marker for severe sepsis.
The authors concluded, "It is tempting to think that measurement of suPAR may be used for triage to determine which patients with sepsis may require more comprehensive monitoring, as high suPAR levels in the emergency department may predict the need for more intensive therapeutic intervention." The study was published in the September 2012 issue of the Journal of Internal Medicine.
Related Links:
Satakunta Central Hospital
ViroGates
Roche Diagnostics
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Biological Indicator Vials
BI-O.K.
New
Centrifuge
Hematocrit Centrifuge 7511M4
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
